 | Experience makes the difference:
BioPharma Solutions, a business unit of Baxter, can help support your commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and more. Talk to us in April at BIO in Chicago or Interphex in NY. | |
| Health Care & Policy |  |  | | - Big Pharma can't quit India despite patent defeat, experts say
 Western drugmakers can't afford to ignore India, which is expected to be the eighth-largest market for drugs within three years, despite suffering a landmark patent setback. "Companies will definitely get cautious, and it definitely means a change in their business model, but I don't think they will pull out," IMS Health's Amit Backliwal said. Experts said makers of brand-name drugs need to develop innovative business models for the country, including collaborating with domestic companies to create less-expensive products, some analysts say. Reuters (4/2)       - Genmab's multiple myeloma drug wins fast-track status
The FDA granted fast-track status to daratumumab, an experimental multiple myeloma drug being developed by Genmab and Janssen Biotech. The designation covers patients who already received at least three lines of treatments including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a PI and an IMiD, this article says. RTT News (4/2) | Company & Financial News | | | | - Funding round brings in $9.2M for organ-on-a-chip maker
Biotech startup Hurel secured $9.2 million in a Series A funding round led by Spring Mountain Capital. The firm will use part of the proceeds to commercialize its lead product, known as organ-on-a-chip or human-on-a-chip, "that replicates the human liver, using living cells," this article says. MedCityNews.com (4/3) | Industry Deals | | | | - BIND, Pfizer ally to develop highly targeted Accurins therapies
Pfizer and BIND Therapeutics agreed to collaborate in the development and marketing of Accurins, a new class of highly targeted and programmable treatments, using the latter's Medicinal Nanoengineering platform. The partners will jointly conduct preclinical research, and Pfizer has the right to develop and market the Accurins it chooses. BIND could get $50 million in upfront and development milestone fees from Pfizer. BIND is also eligible to receive around $160 million in regulatory and sales milestone fees for each Accurin that is commercialized, plus sales royalties. Genetic Engineering & Biotechnology News (4/3) | Food & Agriculture | | | | - Some U.S. farming groups want to extend biotech rider
Several U.S. farm groups are backing a provision in a Senate spending bill that permits farmers to continue growing biotech crops despite a court challenge to a variety's regulatory approval. "We'll certainly try to get that language put into the farm bill," said Danny Murphy, president of the American Soybean Association. "We think it's important farmers have the certainty once they plant a crop they would be able to harvest it," he said. Reuters (4/3) | Industrial & Environmental | | | | - Study points to emissions-free production of hydrogen fuel
Researchers at Virginia Tech have developed technology to produce hydrogen from plant sugar xylose, potentially paving the way for an environmentally friendly way of making hydrogen fuel from any biomass. "Our new process could help end our dependence on fossil fuels," said Y.H. Percival Zhang, a professor of biological systems engineering at Virginia Tech. Most commercially available hydrogen fuel is made from natural gas using a costly process that releases a vast amount of pollutants into the air, researchers said. United Press International (4/3) | News from BIO | | | | - Save on energy costs through BIO's newest cost-savings program
BIO has recently aligned with APPI Energy, an energy consulting firm, to assist member companies with reducing their energy expenses. APPI Energy, the preferred energy consultant of 140 trade associations and chambers of commerce nationwide, provides solutions to reduce electricity and natural gas costs at no risk or obligation to member companies. Through this program, APPI Energy offers specialized energy cost reduction services, including the identification of reliable and competitive energy supplies for member companies and the obtaining of competitive bids from the preferred suppliers in deregulated energy markets. Learn more.
| SmartQuote | | | |  | Action is a great restorer and builder of confidence. Inaction is not only the result, but the cause, of fear."
--Norman Vincent Peale,
American minister and author  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, April 03, 2013
- Tuesday, April 02, 2013
- Monday, April 01, 2013
- Friday, March 29, 2013
- Thursday, March 28, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment